1609 Kirkham St.
29 articles with Cortexyme, Inc.
Cortexyme, Inc. announced the start of screening in Europe for the GAIN Trial, the company’s ongoing Phase 2/3 clinical study of lead investigational medicine COR388 in subjects with mild to moderate Alzheimer’s disease.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Cortexyme, Inc. announced Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at the Canaccord Genuity Growth Conference on Wednesday, August 7th, 2019 at 9:00 a.m. EDT (6:00 a.m. PDT) in Boston.
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019
Company’s novel approach to addressing Alzheimer’s to be featured in two Developing Topics abstracts at AAIC
The newly expanded CAB will support Cortexyme as its lead investigational gingipain inhibitor, COR388, moves through phase 2/3 clinical development as a potential treatment for patients with mild to moderate Alzheimer’s disease.
Event will be webcast, with Cortexyme presentation expected to start at 2:05 p.m. EDT tomorrow afternoon
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced the closing of its initial public offering of 4,412,000 shares
Cortexyme, Inc. announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions.
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, has announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions, as detailed in the company press release.
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
Cortexyme Announces Phase 2/3 Clinical Trial Based on Transformational Understanding of Alzheimer’s Disease Now Open for Enrollment
The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease
Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.
Cortexyme, Inc. announced the election of veteran biopharma finance executive Christopher J. Senner to the company’s Board of Directors.
Cortexyme to Present Preclinical and Clinical Data Supporting Its Novel Investigational Alzheimer’s Treatment At AD/PD 2019
Cortexyme, Inc. announced it will convene an educational session at AD/PD™ 2019, the 14th International Conference on Alzheimer’s & Parkinson’s Diseases, which is taking place March 26-31 in Lisbon, Portugal.
The experienced biopharmaceutical executives join Cortexyme’s board following a foundational publication in Science Advances and as lead compound COR388 advances into late-stage clinical development in mild-to-moderate AD.
February 1 Research Roundup: Alzheimer’s, Gum Disease and Gut Bacteria, New Understanding of Chol...
2/1/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Sometimes it seems like just about every disease, including heart attacks, have been linked to gum disease. And sometimes it seems like just about everything from aluminum pots to herpes virus has been linked to Alzheimer’s.
Cortexyme Announces Key Leadership Appointments in Clinical Development and Finance to Support Next Stage of Growth
Veteran clinical development professional Michael Detke, M.D., Ph.D., has been appointed Chief Medical Officer and Chris Lowe, a longtime life sciences finance expert, is now the company’s Chief Financial Officer